



(12) **United States Patent**
Lluel et al.

(10) **Patent No.:** **US 9,511,061 B2**
(45) **Date of Patent:** **Dec. 6, 2016**

(54) **INCONTINENCE TREATMENT METHODS**
(75) Inventors: **Philippe Lluel**, Ramonville Saint Agne (FR); **Stefano Palea**, Toulouse (FR)
(73) Assignee: **IXALTIS**, Toulouse (FR)
(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 1548 days.

(21) Appl. No.: **12/158,444**
(22) PCT Filed: **Dec. 20, 2006**
(86) PCT No.: **PCT/FR2006/051396**
§ 371 (c)(1),
(2), (4) Date: **Jun. 20, 2008**
(87) PCT Pub. No.: **WO2007/074291**
PCT Pub. Date: **Jul. 5, 2007**

(65) **Prior Publication Data**
US 2008/0305162 A1 Dec. 11, 2008

(30) **Foreign Application Priority Data**
Dec. 22, 2005 (FR) 05 13163

(51) **Int. Cl.**
A61K 31/445 (2006.01)
(52) **U.S. Cl.**
CPC **A61K 31/445** (2013.01)
(58) **Field of Classification Search**
CPC **A61K 31/445; A61K 31/4465**
See application file for complete search history.

(56) **References Cited**

FOREIGN PATENT DOCUMENTS
EP 0077427 4/1983
EP 0467365 A2 * 1/1992
EP 1199069 4/2002
WO WO 03/063873 A1 * 8/2003
WO WO 2004/089288 A2 * 10/2004

OTHER PUBLICATIONS
Vippagunta et al. 2001, *Advanced Drug Delivery Reviews*, vol. 48, pp. 3-26.*

Lucchelli et al. 1995, "The interaction of antidepressant drugs with central and peripheral (enteric) 5-HT3 and 5-HT4 receptors." *British Journal of Pharmacology*, vol. 114, pp. 1017-1025.*
Bhattacharya et al. *The Journal of Neuroscience*, 2004, 24(24), pp. 5537-5548.*
Doi, T. et al. "Effects of TAK-637, a tachykinin receptor antagonist, on lower urinary tract function in the guinea pig" *European Journal of Pharmacology*, 1999, pp. 297-303, vol. 383.
Rao, S.S. et al. "Diagnosis and Management of Fecal Incontinence" *Am. J. Gastroenterology*, 2004, pp. 1585-1604, vol. 99.
Corsi, M. et al. "Pharmacological analysis of 5-hydroxytryptamine effects on electrically stimulated human isolated urinary bladder" *British Journal of Pharmacology*, 1991, pp. 719-725, vol. 104.
Espey, M. J. et al. "Serotonergic modulation of cat bladder function before and after spinal transection" *European Journal of Pharmacology*, 1995, pp. 173-177, vol. 287.
Robertson, D. W. et al. "Zatosetron, a Potent, Selective, and Long-Acting 5HT₃ Receptor Antagonist: Synthesis and Structure-Activity Relationships" *Journal of Medicinal Chemistry*, 1992, pp. 310-319, vol. 35, No. 2.
Testa, R. et al. "Effect of different 5-hydroxytryptamine receptor subtype antagonists on the micturition reflex in rats" *BJU International*, 2001, pp. 256-264, vol. 87.
Nitti, M. "Duloxetine: A New Pharmacologic Therapy for Stress Urinary Incontinence" *Reviews in Urology*, 2004, pp. S48-S55, vol. 6, Suppl. 3.

* cited by examiner

Primary Examiner — Kara R McMillian
(74) *Attorney, Agent, or Firm* — Saliwanchik, Lloyd & Eisenschenk

(57) **ABSTRACT**
The invention relates to the fields of pharmaceutical chemistry and pharmacological treatments. More specifically, the invention relates to compositions and methods for the treatment of incontinence, voiding disorders associated with lower urinary tract dysfunctions and/or the urethro-vesical and anal sphincter disorders. The invention can be used, for example, for the treatment of pollakiuria, urinary urgency, nocturia or enuresis, true faecal incontinence, functional faecal incontinence (FFI), passive faecal incontinence, faecal urgency and/or faecal seepage. The invention is suitable for preventive or curative use with all mammals, particularly humans.

13 Claims, 3 Drawing Sheets